DOCSLIB.ORG

Pharmacist Involvement in the Management of Adverse Effects

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacist Involvement in the Management of Adverse Effects 9/23/2011 Objectives 1. Identify patients at high risk for the following adverse effects: nausea and/or vomiting, mucositis, and peripheral neuropathy 2. Describe treatment options for chemotherapy induced nausea and vomiting based on the chemotherapy emetic Lindsey Dayer, Pharm.D. potential Assistant Professor 3. List 3 treatment options for management of UAMS College of Pharmacy chemotherapy induced peripheral neuropathy 4. Name 2 topical treatments and 1 oral treatment for management of targeted therapy induced rash 5. Identify 3 indications for initial treatment with vancomycin in patients with febrile neutropenia Technician Objectives I have nothing to disclose 1. Review common adverse effects associated with chemotherapy 2. Recognize agents used to treat chemotherapy induced nausea and vomiting, mucositis, peripheral neuropathy, rash, and febrile neutropenia 3. Compare and contrast the different agents used to treat chemotherapy induced nausea and vomiting Side effects of chemotherapy may lead to increased morbidity and mortality, increased cost of cancer care, and decreased quality of life. 1 9/23/2011 As the pharmacist, we can contribute by adding specific drug-related knowledge and offering patient-related services. Chemotherapy Induced Nausea and Vomiting (CINV) Pathophysiology of CINV There was a significant impact on patients’ daily functioning and quality of life in those who developed chemotherapy induced nausea and vomiting Types of CINV Risk Factors for Acute-Onset CINV Younger age (<50 y/o) Anticipatory Female Acute Poor control of symptoms in prior cycles Delayed History of motion sickness or nausea with Breakthrough pregnancy Refractory Anxiety/depression Absence of alcoholism 2 9/23/2011 High Emetic Risk Intravenous Chemotherapy Other Risk Factors for CINV Delayed-Onset CINV AC combination defined Dacarbazine Female as either doxorubicin or Doxorubicin > 60 mg/m² Poor control of symptoms in acute onset epirubicin with Epirubicin > 90 mg/m² cyclophosphamide Chemotherapy regimens with higher doses and Ifosfamide ≥ 10 g/m² faster infusion times Carmustine > 250 mg/m² Mechlorethamine Increasing number of cycles or chemotherapy Cisplatin ≥ 50 mg/m² Streptozocin regimens administered over several days Cyclophosphamide > Combination regimens 1,500 mg/m² Most predictive factor: chemotherapy agent’s tendency to cause CINV Moderate Emetic Risk IV Chemotherapy Low Emetic Risk IV Chemotherapy Aldesleukin > 12-15 million Dactinomycin Amifostine ≤ 300 mg Ixabepilone international units/m² Daunorubicin Aldesleukin ≤ 12 million Methotrexate > 50 mg/m² < 250 Amifostine > 300 mg/m² Doxorubicin ≤ 60 mg/m² international units/m² mg/m² Arsenic trioxide Epirubicin ≤ 90 mg/m² Cabazitaxel Mitomycin Azacitidine Idarubicin Cytarabine (low dose) 100-200 Mitoxantrone Bendamustine Ifosfamide < 10 g/m² mg/m² Paclitaxel Busulfan Interferon alfa ≥ 10 million Docetaxel Paclitaxel-albumin Carboplatin international units/m² Doxorubicin (liposomal) Pemetrexed Carmustine ≤ 250 mg/m² Irinotecan Eribulin Pentostatin Cisplatin < 50 mg/m² Melphalan Etoposide Pralatrexate Clofarabine Methotrexate ≥ 250 mg/m² 5-Fluorouracil Romidepsin Cyclophosphamide ≤ 1,500 Oxaliplatin Floxuridine Thiotepa mg/m² Temozolomide Gemcitabine Topotecan Cytarabine > 200 mg/m² Interferon alfa > 5 < 10 million international units/m² Moderate to High Emetic Risk Minimal Emetic Risk IV Chemotherapy Oral Chemotherapy Agents Alemtuzumab Ipilimumab Altretamine Asparaginase Methotrexate ≤ 50 mg/m² Bevacizumab Nelarabine Busulfan (≥ 4 mg/day) Bleomycin Ofatumumab Bortezomib Panitumumab Cyclophosphamide (≥ 100 mg/m²/day) Cetuximab Pegaspargase Estramustine Cladribine (2- Peginterferon chlorodeoxyadenosine) Rituximab Etoposide Cytarabine < 100 mg/m² Temsirolimus Lomustine (single day) Decitabine Trastuzumab Denileukin diftitox Valrubicin Procarbazine Dexrazoxane Vinblastine Fludarabine Vincristine Temozolomide (>75 mg/m²/day) Interferon alpha ≤ 5 million Vinorelbine international units/m² 3 9/23/2011 Minimal to Low Emetic Risk Emesis Prevention for IV Chemotherapy Oral Chemotherapy Agents High Emetic Moderate Low Emetic Minimal Risk Emetic Risk Risk Emetic Risk Bexarotene Melphalan Busulfan (< 4 mg/day) Mercaptopurine Day 1 5-HT3 Antagonist 5-HT3 Antagonist Dexamethasone No routine Capecitabine Methotrexate AND AND OR prophylaxis Chlorambucil Nilotinib Dexamethasone Dexamethasone Metoclopramide Cyclophosphamide (< 100 Pazopanib AND AND OR mg/m²/day) Sorafenib Neurokinin 1 (Neurokinin 1 Prochlorperazine Dasatinib Sunitinib Antagonist Antagonist) (start prior to Erlotinib Temozolomide (≤ 75 mg/m²/day) chemo) Everolimus Thalidomide Days 2-3(4) Dexamethasone 5-HT3 Antagonist Fludarabine Thioguanine (days 2-4) AND (days 2-3) OR Geftinib Topotecan Neurokinin 1 Dexamethasone Hydroxyurea Tretinoin Antagonist (days (days 2-3) OR 2-3) (Neurokinin 1 Imatinib Vandetanib Lapatinib Antagonist) Vorinostat Lenalidomide Breakthrough Lorazepam, dronabinol, haloperidol, metoclopramide, olanzapine, scopolamine, Medications prochlorperazine, promethazine, 5-HT3 antagonists, dexamethasone Prevention of Anticipatory Nausea and Emesis Prevention for Oral Chemotherapy Vomiting Start before chemotherapy and continue daily Use optimal antiemetic therapy during every cycle of treatment High to moderate emetic risk PO granisetron or PO ondansetron Behavioral therapy Low to minimal emetic risk Recommend PRN initially, then if not Relaxation/systemic desensitization controlled, may switch to: Hypnosis/guided imagery Metoclopramide 10-40 mg PO, then every 4-6 h PRN Music therapy OR Acupuncture/acupressure Prochlorperazine 10 mg PO, then every 4-6 h PRN Lorazepam PO the night before and morning of OR treatment OR alprazolam PO TID beginning on the Haloperidol 1-2 mg PO every 4-6 h PRN If continued N/V, recommend PO night before treatment 5-HT3 antagonists Treatment of Breakthrough Nausea and Vomiting Nausea and Vomiting Prevention Conduct a careful re-evaluation of emetic risk, disease Patient education status, concurrent illnesses, and medications Prevention Prevention Prevention Clarify that the best regimen is being administered Stress to the patient importance of taking antiemetics Give an additional agent from a different drug class PRN Encourage patient to “use” prn medication If controlled, continue breakthrough medications on a Life-style modifications schedule, not PRN If not controlled, consider changing to higher-level primary treatment 4 9/23/2011 Dietary Approaches to Manage Nausea Dietary Approaches to Manage Vomiting Eat foods that are easy on your stomach Prevent nausea Eat 5 or 6 small meals each day Wait for vomiting to stop before eating or drinking Do not skip meals and snacks Once the vomiting stops, drink small amounts of clear Choose foods that appeal to you liquids Sip only small amounts of liquids during meals Once you can drink clear liquids without vomiting, try Eat dry toast or crackers before getting out of bed if full-liquid foods and drinks you have nausea in the morning Eat more small meals instead of less larger meals Plan when it is best for you to eat and drink Case #1 AB is a 49 year old male recently diagnosed with head and neck cancer. He will begin treatment today with Cisplatin 100 mg/m2 every 3 weeks for 3 doses. Which antiemetic regimen should AB receive prior to chemotherapy? a. Ondansetron + Dexamethasone + aprepitant b. Ondansetron + Dexamethasone + prochlorperazine for breakthrough c. Dexamethasone + prochlorperazine for break through d. Ondansetron + Dexamethasone Mucositis 5 9/23/2011 Pathophysiology of Mucositis Pathophysiology of Mucositis Epithelial lining of the GI tract turns over every 7-14 Usually progresses in a stepwise fashion days Asymptomatic redness/erythema occurring 0-5 days Ranges from mild inflammation to bleeding after therapy ulcerations Desquamation with white patches occurring 0-7 days Affects non-keratinized oral mucosa (labial, buccal after therapy and soft-palate mucosa, floor of the mouth, ventral Contiguous pseudomembranes occurring 6-12 days after aspect of the tongue) therapy Painful lesions with or without ulceration occurring 12- 16 days after therapy Lalla et al. Oral Toxicity. The Chemotherapy Source Anthony et al. Support Care Cancer. 2006; 14: 56-8 Book. 4th Edition. 2008: 115-35 WHO Grading System for Mucositis Chemotherapy-Induced Mucositis Grade 0: None 40-75% will experience mucositis Grade 1: Soreness +/- redness, no ulceration 70-80% undergoing bone marrow transplantation with Grade 2: Redness, ulcers. Patients can swallow solid radiation-based condition regimens will develop diet mucositis Grade 3: Ulcers, extensive redness. Patients cannot Course parallels neutrophil nadir swallow solid diet Continuous infusions cause more mucositis than short Grade 4: Oral mucositis to the extent that eating is not IV infusions possible Chemotherapy combined with radiation leads to worse mucositis than either given alone Scully et al. Head & Neck. 2003; 25: 1057-70 Risk Factors for Mucositis Outcomes of Mucositis Pre-existing oral lesions Mucositis can lead to: Poor dental hygiene or ill-fitting dentures Delaying subsequent chemotherapy cycles Combined modality treatment with chemotherapy Dosage reductions plus radiation Discontinuation of chemotherapy regimens Ethnicity (Caucasians > African Americans) Feeding tubes Development of fever
Load more

Recommended publications
  • Treatment of Localized Extranodal NK/T Cell Lymphoma, Nasal Type: a Systematic Review Seok Jin Kim†, Sang Eun Yoon† and Won Seog Kim*
    Kim et al. Journal of Hematology & Oncology (2018) 11:140 https://doi.org/10.1186/s13045-018-0687-0 REVIEW Open Access Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review Seok Jin Kim†, Sang Eun Yoon† and Won Seog Kim* Abstract Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently recommended treatments are based mainly on the results of phase II studies and retrospective analyses. Because the previous outcomes of anthracycline-containing chemotherapy were poor, non- anthracycline-based chemotherapy regimens, including etoposide and L-asparaginase, have been used mainly for patients with localized nasal ENKTL. Radiotherapy also has been used as a main component of treatment because it can produce a rapid response. Accordingly, the combined approach of non-anthracycline-based chemotherapy with radiotherapy is currently recommended as a first-line treatment for localized nasal ENKTL. This review summarizes the different approaches for the use of non-anthracycline-based chemotherapy with radiotherapy including concurrent, sequential, and sandwich chemoradiotherapy, which have been proposed as a first-line treatment for newly diagnosed patients with localized nasal ENKTL. Keywords: Extranodal NK/T cell lymphoma, Chemoradiotherapy, Localized disease Background Treatment for newly diagnosed patients with localized Extranodal natural killer/T cell lymphoma (ENKTL), nasal nasal ENKTL type, is a rare subtype of non-Hodgkin lymphoma [1].
    [Show full text]
  • Assessment of Overall Survival, Quality of Life, And
    Supplementary Online Content Salas-Vega S, Iliopoulos O, Mossialos E. Assesment of overall survival, quality of life, and safety benefits associated with new cancer medicines [published online December 29, 2016]. JAMA Oncol. doi:10.1001/jamaoncol.2016.4166 eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003- 2013 eTable 2. Regulatory evidence in support of classification of drug clinical benefits eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, sorted by magnitude of clinical benefits eTable 3. Interagency agreement–Krippendorff’s alpha coefficients eMethods This supplementary material has been provided by the authors to give readers additional information about their work. Online-Only Supplement © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/25/2021 Clinical value of cancer medicines Contents eExhibits ......................................................................................................................................................... 3 eTable 1. Therapeutic profile of all cancer medicines approved by the FDA between 2003- 2013 (Summary of eTable 2) ................................................................................................................... 3 eTable 2. Regulatory evidence in support of classification of drug clinical benefits ....................... 6 eFigure 1. Number of cancer drugs that were evaluated by all three HTA agencies, sorted by magnitude of clinical benefits
    [Show full text]
  • RESEARCH ARTICLE Lobaplatin Combined Floxuridine/Pirarubicin
    DOI:http://dx.doi.org/10.7314/APJCP.2014.15.5.2057 The Effect Observation of LBP-based TACE for Unresectable Primary Hepatocellular Carcinoma RESEARCH ARTICLE Lobaplatin Combined Floxuridine/Pirarubicin-based Transcatheter Hepatic Arterial Chemoembolization for Unresectable Primary Hepatocellular Carcinoma Chang Zhao1, Xu-Jie Wang2*, Song Wang2*, Wei-Hua Feng2, Lei Shi2, Chun- Peng Yu2 Abstract Purpose: To assess the effect and safety of lobaplatin combinated floxuridine /pirarubicin in transcatheter hepatic arterial chemoembolization(TACE) of unresectable primary liver cancer. Patients and Methods: TACE combined with the chemotherapy regimen was used to treat 34 unresectable primary liver cancer patients. DSA/ MRI/CT/blood routine examinations were used to evaluate short term activity and toxicity after 4-5 weeks, the process being repeated if necessary. Results: Among the 34 cases, 1 (2.9%) showed a complete response, 21 (61.7%) a partial response, 8 (23.5%) stable disease, and 4 progressive disease, with a total effective rate of 67.6%. The content of alpha fetoprotein dropped by over 50% in 20 cases (58.8%). The rate of recovery was hepatalgia (88.2%), ascites (47.1%), appetite (55.9%), Performance Status(30.4%). The median follow-up time (MFT) was 281 days (63-558 days), and median progression-free survival was 118.5 days (95%, CI:88.8-148.2days). Adverse reactions (III-IV grade) were not common, with only 4 cases of vomiting and 2 cases of thrombocytopenia (III grade). Conclusions: Lobaplatin-based TACE is an effective and safe treatment for primary liver cancer. Keywords: Primary hepatic carcinoma - chemoembolization - platinum chemotherapy - clinical response Asian Pac J Cancer Prev, 15 (5), 2057-2060 Introduction LBP-based TACE, male 29 cases, female 5 cases, average age for 57.2±10.7 years, 12 cases were biopsy-proven, Hepatocellular carcinoma (HCC) is a common 22 cases were in line with the China Cancer Association malignant tumor .
    [Show full text]
  • Australian Public Assessment Report for Aminolevulinic Acid Hcl
    Australian Public Assessment Report for Aminolevulinic acid HCl Proprietary Product Name: Gliolan Sponsor: Specialised Therapeutics Australia Pty Ltd March 2014 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health, and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website < http://www.tga.gov.au>. About AusPARs · An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Hodgkin Lymphoma Treatment Regimens
    HODGKIN LYMPHOMA TREATMENT REGIMENS (Part 1 of 5) Clinical Trials: The National Comprehensive Cancer Network recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced health care team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are provided only to supplement the latest treatment strategies. These Guidelines are a work in progress that may be refined as often as new significant data become available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. Classical Hodgkin Lymphoma1 Note: All recommendations are Category 2A unless otherwise indicated. Primary Treatment Stage IA, IIA Favorable (No Bulky Disease, <3 Sites of Disease, ESR <50, and No E-lesions) REGIMEN DOSING Doxorubicin + Bleomycin + Days 1 and 15: Doxorubicin 25mg/m2 IV push + bleomycin 10units/m2 IV push + Vinblastine + Dacarbazine vinblastine 6mg/m2 IV over 5–10 minutes + dacarbazine 375mg/m2 IV over (ABVD) (Category 1)2-5 60 minutes.
    [Show full text]
  • Ciera L. Patzke, Alison P. Duffy, Vu H. Duong, Firas El Chaer 4, James A
    Journal of Clinical Medicine Article Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia Ciera L. Patzke 1, Alison P. Duffy 1,2, Vu H. Duong 1,3, Firas El Chaer 4, James A. Trovato 2, Maria R. Baer 1,3, Søren M. Bentzen 1,3 and Ashkan Emadi 1,3,* 1 Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA; [email protected] (C.L.P.); aduff[email protected] (A.P.D.); [email protected] (V.H.D.); [email protected] (M.R.B.); [email protected] (S.M.B.) 2 School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA; [email protected] 3 School of Medicine, University of Maryland, Baltimore, MD 21201, USA 4 School of Medicine, University of Virginia, Charlottesville, VA 22908, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-410-328-2596 Received: 10 January 2020; Accepted: 13 February 2020; Published: 16 February 2020 Abstract: Currently, no standard of care exists for the treatment of relapsed or refractory acute myeloid leukemia (AML). We present our institutional experience with using either CLAG-M or HAM-pegA, a novel regimen that includes pegaspargase. This is a retrospective comparison of 34 patients receiving CLAG-M and 10 receiving HAM-pegA as first salvage cytotoxic chemotherapy in the relapsed or refractory setting. Composite complete response rates were 47.1% for CLAG-M and 90% for HAM-pegA (p = 0.027).
    [Show full text]
  • Palifermin (Kepivance™) in the Treatment of Mucositis
    Session V • From cell biology to cell therapy Palifermin (Kepivance™) in the treatment of mucositis [haematologica reports] 2005;1(8):41-45 EMMANOUILIDES C n patients undergoing high dose chemo- factor (KGF) is a 28 kD member of the therapy and hematopoietic stem cell fibroblast growth factor family with epithe- Associate Profesor transplant, oral mucositis (OM) is one of lial cell proliferative properties.26 Palifermin of Medicine, UCLA, I Division Haematology-Oncology, the most debilitating and annoying side (Kepivance™) is a truncated, recombinant Thessaloniki, Greece effects. This complication results from form of human keratinocyte growth factor cytotoxic injury to the epithelial lining of (rHuKGF) that has been approved in the the oropharyngeal mucosa, although USA in 2004 to decrease the incidence and lesions of the whole gastrointestinal tract duration of severe OM in patients with also occur.1 The severity of OM varies from hematologic malignancies receiving myelo- erythema and edema accompanied by mild toxic therapy requiring HSCT support. Pal- soreness to full mucosal thickness ulcera- ifermin (recombinant human keratinocyte tions penetrating into the submucosa, growth factor) is an N-terminal, truncated often resulting in severe pain requiring version of endogenous keratinocyte growth narcotic analgesia and impaired swallow- factor with biologic activity similar to that ing, prolonged hospitalization, and of the native protein, but with increased increased risks for infections and poten- stability 26 In animal models of chemother- tially life-threatening sequelae.2,3 Between apy, radiotherapy, and hematopoietic stem- 40% to 80% of cancer patients undergo- cell transplantation27,28 palifermin protected ing intensive treatment regimens requiring several types of epithelial tissues.
    [Show full text]
  • In Vitro and in Vivo Reversal of Resistance to 5-Fluorouracil in Colorectal Cancer Cells with a Novel Stealth Double-Liposomal Formulation
    British Journal of Cancer (2007) 97, 919 – 926 & 2007 Cancer Research UK All rights reserved 0007 – 0920/07 $30.00 www.bjcancer.com In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation 1 1 1 1 2 3 *,1 R Fanciullino , S Giacometti , C Mercier , C Aubert , C Blanquicett , P Piccerelle and J Ciccolini 1 2 EA3286-Laboratoire de Pharmacocine´tique, Universite´ de la Me´diterrane´e, Marseille, France; Department of Medicine, School of Medicine, Emory 3 University, Atlanta, GA, USA; Laboratoire de Pharmacie Gale´nique, Faculte´ de Pharmacie, 27 Bd Jean Moulin, Marseille 05 13385, France Drug resistance is a major cause of treatment failure in cancer chemotherapy, including that with the extensively prescribed antimetabolite, 5-fluorouracil (5-FU). In this study, we tried to reverse 5-FU resistance by using a double-punch strategy: combining 5-FU with a biochemical modulator to improve its tumoural activation and encapsulating both these agents in one same stealth liposome. Experiments carried out in the highly resistant, canonical SW620 human colorectal model showed a up to 80% sensitisation to 5-FU when these cells were treated with our liposomal formulation. Results with this formulation demonstrated 30% higher tumoural drug uptake, better activation with increased active metabolites including critical-5-fluoro-2-deoxyuridine-5-monophos- phate, superior inhibition (98%) of tumour thymidylate synthase, and subsequently, higher induction of both early and late apoptosis. Drug monitoring showed that higher and sustained exposure was achieved in rats treated with liposomal formulation. When examined in a xenograft animal model, our dual-agent liposomal formulation caused a 74% reduction in tumour size with a mean doubling in survival time, whereas standard 5-FU failed to exhibit significant antiproliferative activity as well as to increase the lifespan of tumour-bearing mice.
    [Show full text]
  • NOV 1 72010 1.0 Submitter
    510(k) SUMMARY NOV 1 72010 1.0 Submitter Name Shen Wei (USA) Inc. Street Address 33278 Central Ave., Suite 102 Union City, CA. 94587 Phone No. (510)429-8692 Fax No. (510)487-5347 Date of Summary Prepared: 08/12/10 Prepared by: Albert Li 2.0 Name of the device: Glove Proprietary or Trade Name: Blue and Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs Common Name: Exam gloves Classification Name: Patient examination glove, Specialty Chemotherapy'(per 21 CFR 880.6250 product code LZC) Classification Information: Class I Nitrile patient examination glove 8OLZC, powder-free and meeting all the requirements of ASTM D 631 9-O0a-05 and is tested with chemotherapy drugs according to ASTM D 6978-05. 3.0 Identification of the Legally Marketed Device: Blue and Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera Regulatory Class I Nitrile patient examination Product code: 8OLZA 5 10(k): K092411 4.0 Description of the Device: Blue and Red with Pearlescent® Pigment, Powder Free Nitrite Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs meets all the requirements of ASTM D 6978-05, ASTM D63 19-00a(2005) and FDA 21 CFT 880.6250. 5.0 Intended Use of Device: Product: Red with Pearlescent® Pigment, Powder Free Nitrile Examination Gloves with Aloe Vera, Tested for use with Chemotherapy Drugs A disposable device intended for medical purpose that is worn on the examiner's hand to prevent contamination between patient and examiner. This device is single use only.
    [Show full text]
  • Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake
    International Journal of Molecular Sciences Article Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake Anna Aviñó 1,2,*, Anna Clua 1,2 , Maria José Bleda 1 , Ramon Eritja 1,2,* and Carme Fàbrega 1,2 1 Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, E-08034 Barcelona, Spain; [email protected] (A.C.); [email protected] (M.J.B.); [email protected] (C.F.) 2 Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Jordi Girona 18-26, E-08034 Barcelona, Spain * Correspondence: [email protected] (A.A.); [email protected] (R.E.); Tel.: +34-934-006-100 (A.A.) Abstract: Conjugation of small molecules such as lipids or receptor ligands to anti-cancer drugs has been used to improve their pharmacological properties. In this work, we studied the biological effects of several small-molecule enhancers into a short oligonucleotide made of five floxuridine units. Specifically, we studied adding cholesterol, palmitic acid, polyethyleneglycol (PEG 1000), folic acid and triantennary N-acetylgalactosamine (GalNAc) as potential enhancers of cellular uptake. As expected, all these molecules increased the internalization efficiency with different degrees depending on the cell line. The conjugates showed antiproliferative activity due to their metabolic activation by nuclease degradation generating floxuridine monophosphate. The cytotoxicity and apoptosis assays showed an increase in the anti-cancer activity of the conjugates related to the floxuridine oligomer, but this effect did not correlate with the internalization results. Palmitic and folic acid conjugates provide the highest antiproliferative activity without having the highest internalization Citation: Aviñó, A.; Clua, A.; Bleda, results.
    [Show full text]
  • Bendamustine and Cytosine Arabinoside: a Highly Synergistic Combination Visco C*, Carli G and Rodeghiero F Further DNA Synthesis [24]
    Open Access Austin Journal of Cancer and Clinical Research Editorial Bendamustine and Cytosine Arabinoside: A Highly Synergistic Combination Visco C*, Carli G and Rodeghiero F further DNA synthesis [24]. The synergistic effect of bendamustine Department of Cell Therapy and Hematology, San Bortolo and cytarabine could be related to the individual mechanism of Hospital, Italy action of the two drugs, whose serial administration would avoid *Corresponding author: Carlo Visco, Department of the saturation of the common pathways. Cells escaping the cell cycle Cell Therapy and Hematology, San Bortolo Hospital, Via arrest induced by bendamustine and trying to repair their damage Rodolfi 37, 36100 Vicenza, Italy, Tel: +39 0444 753626; would be prone to incorporate the metabolite ara-CTP into DNA, Fax: +39 0444 920708; Email: [email protected] as reported by Staib [19] in acute myeloid leukemia cells. Indeed, the Received: January 07, 2015; Accepted: March 16, sequential treatment with bendamustine followed by cytarabine was 2015; Published: April 03, 2015 proven to be more effective than simultaneous addition of the two drugs (Figure 2) [21-23]. The S phase of the cell cycle is a crucial step Editorial of replication in mantle cell lymphoma (MCL) cells, where cyclin D1 Bendamustine is a bifunctional compound that has shown clinical overexpression deregulates the cell cycle at the G1/S phase transition, activity against various human cancers including non-Hodgkin’s and and is likely the engine continuously pushing cells towards S-phase Hodgkin’s lymphoma [1,2], chronic lymphocytic leukemia (CLL) [3], (Figure 3). Indeed, both drugs are known to be particularly active in multiple myeloma [4,5], breast cancer [6], and small-cell lung cancer patients with MCL.
    [Show full text]
  • Valrubicin (Valstar) Reference Number: CP.PHAR.439 Effective Date: 09.04.18 Last Review Date: 11.20 Line of Business: Medicaid, HIM Revision Log
    Clinical Policy: Valrubicin (Valstar) Reference Number: CP.PHAR.439 Effective Date: 09.04.18 Last Review Date: 11.20 Line of Business: Medicaid, HIM Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Valrubicin (Valstar®) is an anthracycline. FDA Approved Indication(s) Valstar is indicated for the intravescial therapy of bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Valstar is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Bladder Cancer (must meet all): 1. Diagnosis of recurrent or persistent CIS of the urinary bladder; 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Member meets one of the following (a or b)*: a. Failure of intravesical BCG treatment, unless contraindicated or clinically significant adverse effects are experienced; b. Adjuvant intravesical chemotherapy for non-muscle invasive bladder cancer in the event of a BCG shortage (see Appendix D for information on BCG shortage); *Prior authorization may be required for BCG immunotherapy 5. Request meets one of the following (a or b):* a. Dose does not exceed 800 mg per week; b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).
    [Show full text]